Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs
15 3월 2022 - 5:30AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on
transforming medicines to transform lives, today announced the
appointment of Brandi Robinson to the newly created position of
Senior Vice President, Corporate Affairs.
“We are pleased to welcome Brandi to the Avadel team as our
Senior Vice President, Corporate Affairs as we continue to advance
once-at-bedtime FT218 for the treatment of excessive daytime
sleepiness or cataplexy in adults with narcolepsy,” said Greg
Divis, Chief Executive Officer of Avadel. “Brandi brings a wealth
of corporate affairs experience in the biopharmaceutical industry,
which will support the company as we expand. We look forward to
working alongside Brandi as we continue to strengthen our
operational and commercial infrastructure to support our important
mission of transforming lives with much-needed therapeutics.”
“It’s an exciting time to join Avadel, as the Company continues
to build operational capabilities for the potential launch of
FT218,” said Brandi Robinson. “People living with narcolepsy
deserve relief from not only the debilitating symptoms of
narcolepsy, but also from the burden of waking up in the middle of
the night to take a second dose of their medication. I look forward
to joining this strong team as we advance preparations to bring
FT218 to patients.”
Brandi Robinson is an accomplished communications executive that
brings more than 25 years of experience in the pharmaceuticals,
medical device and consumer health industries specializing in
strategic communications, media relations, issues management,
patient education campaigns, corporate reputation, and product and
internal communications. She most recently served as Chief
Corporate Affairs Officer for Rafael Holdings, Inc., a company
focused on the development of novel cancer and immune metabolism
therapeutics. At Rafael Holdings, Brandi led the communications,
corporate affairs and patient advocacy functions, and served as a
member of the Executive Committee. Prior to Rafael Holdings, she
was Chief Communications Officer at Mallinckrodt plc, and before
that, Brandi led communications for Seattle Genetics, Sanofi U.S.
and Novartis. Earlier in her career, Brandi held numerous
healthcare public relations roles. She earned a B.A. in
Communication, Journalism and Related Programs from Fairleigh
Dickinson University.
In connection with the hiring of Brandi Robinson, the
Compensation Committee of the Board of Directors approved the grant
of non-statutory options to purchase an aggregate of 215,000
ordinary shares under Avadel’s 2021 Inducement Plan. The award was
granted as an inducement material to Ms. Robinson’s acceptance of
employment with Avadel in accordance with Nasdaq Listing Rule
5635(c)(4). The options have an exercise price of $7.22 per share,
which is equal to the closing price of Avadel’s American Depositary
Shares as reported by Nasdaq on March 11, 2022. The options have a
ten year term and vest over four years, with 25% vesting on the
one-year anniversary of Ms. Robinson’s first day of employment with
Avadel and the remainder vesting in equal annual installments of
25% for the three years thereafter, subject to her continued
service with Avadel on each such vesting date. The options are
subject to the terms and conditions of Avadel’s 2021 Inducement
Plan and the terms and conditions of the award agreement covering
the grant.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical
company focused on transforming medicines to transform lives. Our
approach includes applying innovative solutions to the development
of medications that address the challenges patients face with
current treatment options. Our current lead drug candidate, FT218,
is an investigational formulation of sodium oxybate leveraging our
proprietary drug delivery technology and designed to be taken once
at bedtime for the treatment of excessive daytime sleepiness and
cataplexy in adults with narcolepsy. For more information, please
visit www.avadel.com.
Cautionary Disclosure Regarding Forward-Looking
Statements
This press release includes “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements relate to the Company’s future
expectations, beliefs, plans, strategies, objectives, results,
conditions, financial performance, prospects, or other events. Such
forward-looking statements include, but are not limited to, the
Company’s expectations regarding the therapeutic benefits of FT218,
the preparations for a potential commercial launch of FT218 and the
anticipated contributions of new members of the management team to
the Company’s operations and progress. In some cases,
forward-looking statements can be identified by the use of words
such as “will,” “may,” “could,” “believe,” “expect,” “look
forward,” “on track,” “guidance,” “anticipate,” “estimate,”
“project,” “next steps” and similar expressions, and the negatives
thereof (if applicable).
The Company’s forward-looking statements are based on estimates
and assumptions that are made within the bounds of our knowledge of
our business and operations and that we consider reasonable.
However, the Company’s business and operations are subject to
significant risks, and, as a result, there can be no assurance that
actual results and the results of the company’s business and
operations will not differ materially from the results contemplated
in such forward-looking statements. Factors that could cause actual
results to differ from expectations in the Company’s
forward-looking statements include the risks and uncertainties
described in the “Risk Factors” section of Part I, Item 1A of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2020, which was filed with the Securities and Exchange
Commission (SEC) on March 9, 2021 and subsequent SEC filings.
Forward-looking statements speak only as of the date they are
made and are not guarantees of future performance. Accordingly, you
should not place undue reliance on forward-looking statements. The
Company does not undertake any obligation to publicly update or
revise our forward-looking statements, except as required by
law.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Nicole Raisch GoelzReal
Chemistryngoelz@realchemistry.com (408) 568-4292
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024